CECOG PANCREAS CANCER ACADEMY 5.0

Start Time

14:00

3. February 2021

Finish Time

17:00

7. July 2021

Pancreas Cancer Academy 5.0

Agenda Webinars

Conference Time: 2:00 pm CET

5 min. Opening words, 30 minutes presentation of the individual topic, followed by discussion for 10-15 minutes, Q&A Participants including chat

3. February 2021

Novel Neoadjuvant Treatment concepts for resectable and borderline resectable PAC patient

Speaker: Teresa Macarulla, Spain
Discussants: Eric Van Cutsem, Belgium / Chee Cheng Ean, Singapore

GO TO WEBINAR

17. February 2021

Adjuvant Treatment Options for PAC patients: how aggressive should we be?

Speaker: Julien Taieb, France
Discussants: Harpreet Wasan, UK / Joon Oh Park, Korea

GO TO WEBINAR

24. March 2021

Quality of Life during mPDAC treatment: Utopia or Reality
Has Covid changed our perspective on Quality of Life for mPAC

Speaker: Francesca Pesce, Italy
Discussants: Ali Stunt, UK / Gerald Prager, Austria

GO TO WEBINAR

21. April 2021

mPAC: Oligometastatic Disease

Speaker: Thomas Seufferlein, Germany
Discussants: Massimo Falconi, Italy/ Katsuhiko Uesaka, Japan

GO TO WEBINAR

5. May 2021

Molecular Testing for Treatment Stratification on PAC patients: where do we stand, where do we go

Speaker: Cindy Neuzillet, France
Discussants: Pascal Hammel, France / Masafumi Ikeda, Japan

GO TO WEBINAR

26. May 2021

Frailty versus malnutrition – impact on outcome?
Speaker: Andrea Davis, UK
Discussants: Dominiek De Jonckheere, Belgium / Phil Whelan, UK

GO TO WEBINAR

16. June 2021

Before / After ASCO: Paradigm Changing News
Speaker: Talia Golan, Israel
Discussants: Gerald Prager, Austria / Changhoon YOO, Korea

GO TO WEBINAR

7. July 2021

Modern Treatment Approaches in met.PDAC patients and continuum of care
Speaker: Gerald Prager, Austria
Discussants: Eric van Cutsem, Belgium / Junji Furuse, Japan

GO TO WEBINAR

 

If you are interested in joining the panel discussion, please contact [email protected] who will send afterwards the dial-in details.

 

Supported by

Leave A Reply